SYRINX has extensive experience of developing new methods using state-of-the-art immunological and cell based techniques for pharmacokinetic (PK) sample analysis.
Our laboratory employs various plate and cellbased technologies, such as TR-FIA, ECL, AlphaLISA, iLITE, TR-FRET, RIA, SPR and ELISA, to assess the immunogenicity of biological drugs and vaccines.
Patient monitoring services are now available!
Concentration/activity analysis and immunogenicity testing using the iLite™ technology platform.
SYRINX Bioanalytics, part of the Synexa Life Sciences group, is a Contract Research Organization (CRO) offering a large variety of modern immunoassay techniques for the bioanalysis of Biologicals, Biosimilars, Anti-drug antibodies (immunogenicity testing) and Biomarkers.
SYRINX performs bioanalytical studies in compliance with GLP/GCP and supports GMP analysis for batch release and stability studies.
We are continuously striving to fulfil the latest guideline and white paper requirements offering innovative approaches utilising our strong scientific expertise and responsive communication with the focus on quality and on time delivery.
SYRINX Bioanalytics is included in the OECD principles of good laboratory practice (GLP) and EU good manufacturing practice (GMP analytics) monitoring programs.
SYRINX Bioanalytics offers a wide range of state-of-the-art assay techniques ideal for the bioanalysis of biologicals/biosimilars, anti-drug antibodies, vaccines and biomarkers.
SYRINX is a member of the European Bioanalysis Forum (EBF) together with more than 50 other Pharma and CRO companies.
SYRINX Bioanalytics joins the Synexa Life Sciences Group!
Synexa Life Sciences acquires Syrinx Bioanalytics to expand bioanalysis capabilities in clinical drug development. Synexa Life Sciences BV, a global leader in specialist biomarker and bioanalysis research services, announced 19th of May 2022, that it has acquired the shares of Syrinx Bioanalytics. Read the full press release here.
Synexa Life Sciences will attend the EBF Open Symposium "One year into ICH M10 - Keeping our finger on the pulse" 15-17 Nov 2023 in Barcelona. Meet us at the exhibition area!
Synexa Life Sciences will attend the EBF Focus Workshop "Scientific, Regulatory and Technology Challenges in the Development of Oligonucleotide and Peptide Drugs" 28-29 Apr 2022 in Malaga.
Synexa Life Sciences attended the Gyrolab User Meeting in Lisbon 15-17 May 2023.
Synexa Life Sciences attended the "14th Open Scientific European Immunogenicity Platform (EIP) Symposium on Immunogenicity of Biopharmaceuticals" in Lisbon 26-28 Apr 2023.
Synexa Life Sciences attended the EBF Open Symposium "Towards harmonised implementation of the ICH M10 Guideline" and "The Bioanalytical Compass - Navigating to our True North" 15-18 Nov 2022 in Barcelona.
SYRINX attended the EBF Focus Workshop "Points to Consider on Cut Points" 28-29 Apr 2022.
SYRINX attended the "Biacore Analytics Workshop 2021: Innovation in emerging therapeutics and novel analytical approaches" 30 Nov 2021.Immunogenicity analysis - determination of cut points. We use in-house validated MS Excel-templates for statistical evaluation of cut points according to Shankar et al. (Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products: J. Pharm. Biomed. Anal. 2008, 48/5: 1267-81) and Devanarayan et al. (Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points: AAPS Journal 2017, 19/5: 1487–1498).